Across TCGA pan-cancer cohorts, ABAT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABAT data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ABAT mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ABAT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

UCEC, CCRCC, and LUAD are the cancer types where ABAT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	0.198	1.000	.001	28	view →
CCRCC	OS	Median	II,III,IV	1.000	0.809	.003	28	view →
LUAD	OS	Quartile	II,III,IV	1.000	0.415	<.001	21	view →
HNSC	OS	Median	All	0.615	0.801	.009	4	view →
PDAC	DFS	Tertile	II,III,IV	0.818	0.648	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ABAT tumor-vs-normal RNA expression · all ABAT data types